High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients
Open Access
- 1 January 2006
- journal article
- clinical trial
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 12 (1) , 56-62
- https://doi.org/10.1111/j.1469-0691.2005.01290.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs)Clinical Microbiology & Infection, 2000
- A Novel Complex Mutant β-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum β-Lactamase-Producing KlebsiellaeAntimicrobial Agents and Chemotherapy, 2000
- Ceftazidime-Resistant Enterobacteriaceae Isolates from Three Polish Hospitals: Identification of Three Novel TEM- and SHV-5-Type Extended-Spectrum β-LactamasesAntimicrobial Agents and Chemotherapy, 1998
- Plasmid-Mediated Resistance to Expanded-Spectrum Cephalosporins among Enterobacter aerogenes StrainsAntimicrobial Agents and Chemotherapy, 1998
- A new plasmidic cefotaximase from patients infected withSalmonella typhimuriumInfection, 1992
- CDC definitions for nosocomial infections, 1988American Journal of Infection Control, 1988
- APACHE IICritical Care Medicine, 1985
- Evolution of plasmid-coded resistance to broad-spectrum cephalosporinsAntimicrobial Agents and Chemotherapy, 1985
- Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescensInfection, 1983